Premium
TP53 alterations and clinical outcome in low grade astrocytomas
Author(s) -
Kraus Jürgen A.,
Bolln Carsten,
Wolf Helmut K.,
Neumann Jürgen,
Kindermann Dietmar,
Fimmers Rolf,
Forster Frank,
Baumann Axel,
Schlegel Uwe
Publication year - 1994
Publication title -
genes, chromosomes and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.754
H-Index - 119
eISSN - 1098-2264
pISSN - 1045-2257
DOI - 10.1002/gcc.2870100211
Subject(s) - astrocytoma , immunohistochemistry , pathology , glioma , tumor progression , cancer , cancer research , p53 protein , mutation , biology , gene , medicine , genetics
Thirty‐eight WHO grade II astrocytomas and 10 malignant recurrent gliomas in these patients were examined for the presence of TP53 alterations. Seventeen/38 low grade astrocytomas and 6/10 malignant recurrent tumors harbored mutations of the gene detected by SSCP analysis and direct sequencing of PCR products. TP53 mutations in five out of six high grade mutant tumors were already present in the corresponding low grade astrocytomas. In two cases, TP53 mutations present in the low grade astrocytoma could not be demonstrated in the recurrent glioma. Immunohistochemistry with two different antibodies to the human TP53 protein revealed nuclear immunoreaction of tumor cells in 11/38 low grade and in 8/10 recurrent tumors. There was no correlation between the presence of TP53 alteration and clinical course. We conclude that, although TP53 mutations are detectable in a substantial fraction of WHO grade II astrocytomas, they do not appear to play a role in the malignant progression of these tumors and they are not of prognostic significance. Genes Chromosom Cancer 10:143–149 (1994). © 1994 Wiley‐Liss, Inc.